Brain 17 Vienna
Bevacizumab
• Only low risk for CNS hemorrhage in patients with NSCLC and brain mets who are treated with bevacizumab
• Potentially strong anti-edema activity
• Bevacizumab alone or in combination with chemotherapy in patients with brain mets from NSCLC:
• Median PFS: 7.8 months • Median OS: 14.1 months
• WBRT + bevacizumab in patients with brain mets (REBECA): • Safe, but clinical benefit remains unclear
Socinski et al. J Clin Oncol 2009 De Braganca et al. J Neurooncol 2010 Lévy et al. Ann Oncol 2014
Made with FlippingBook - Online catalogs